ArticleJournal of Crohn's & colitis2012
Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD.
Article in Journal of Crohn's & colitis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Clinical Significance of Mucin Signatures in Inflammatory Bowel Diseases: A Systematic Review of Their Expression Patterns, Polymorphisms, and Post-translational Modifications.Inflammatory bowel diseases · 2026Pooled it
- Quantitative Proteomic Analysis Reveals the Deregulation of Nicotinamide Adenine Dinucleotide Metabolism and CD38 in Inflammatory Bowel Disease.BioMed research international · 2019Trial
- RUNX2 promotes chromatin accessibility and WNT signaling in inflamed intestinal epithelial cells.Mucosal immunology · 2026Article
- Olfactomedin-4Infection and immunity · 2026Article
- RUNX2 promotes epigenetic WNT signaling in inflamed intestinal epithelial cells.bioRxiv : the preprint server for biology · 2025Article
- Olfactomedin 4 in cancer development and progression.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Exploring the Clinical Implication of S100A9 in Ulcerative Colitis and Its Progression to Cancer: A Journey from Inflammation to Cancer.International journal of molecular sciences · 2025Article
- The emerging role of intestinal stem cells in ulcerative colitis.Frontiers in medicine · 2025Review
- Alterations in Ileal Secretory Cells of The DSS-Induced Colitis Model Mice.Acta histochemica et cytochemica · 2024Article
- Molecular Activity of Inflammation and Epithelial-Mesenchymal Transition in the Microenvironment of Ulcerative Colitis.Gut and liver · 2024Observational
- OLFM4 modulates intestinal inflammation by promoting IL-22Communications biology · 2024Article
- Sympathetic activity regulates epithelial proliferation and wound healing via adrenergic receptor αScientific reports · 2023Article
- Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease.Nature communications · 2023Article
- Spatial transcriptome unveils a discontinuous inflammatory pattern in proficient mismatch repair colorectal adenocarcinoma.Fundamental research · 2023Article
- Stiffness Restricts the Stemness of the Intestinal Stem Cells and Skews Their Differentiation Toward Goblet Cells.Gastroenterology · 2023Article
- Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer.Cancer gene therapy · 2023Article
- Comprehensive Analysis of Gene Expression Profiling to Explore Predictive Markers for Eradication Therapy Efficacy againstCancers · 2023Article
- Hypoxia-Driven Changes in a Human Intestinal Organoid Model and the Protective Effects of Hydrolyzed Whey.Nutrients · 2023Article
- Olfactomedin-4 deletion exacerbates DSS-induced colitis through a matrix metalloproteinase-9-dependent mechanism.International journal of biological sciences · 2023Article
- The role of the Notch signalling pathway in the pathogenesis of ulcerative colitis: from the perspective of intestinal mucosal barrier.Frontiers in medicine · 2023Review
Corrections and comments
- Expression of concern · 2022-01-24Civil Proceedings · Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Legal Reasons and/or Threats · · See also: https://doi.org/10.1093/ecco-jcc/jjab225 Journal was previously published by Elsevier until 2015.
- Commented on by
- Erratum issuedCorrection.2023
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOlfactomedin-4 (OLFM4) is a glycoprotein characteristic of intestinal stem cells and apparently involved in mucosal defense of the stomach and colon. Here we studied its expression, regulation and function in IBD.
methodsThe expression of OLFM4, mucins Muc1 and Muc2, the goblet cell differentiation factor Hath1 and the proinflammatory cytokine IL-8 was measured in inflamed or noninflamed colon in IBD patients and controls. OLFM4 protein was located by immunohistochemistry, quantified by Dot Blot and its binding capacity to defensins HBD1-3 was investigated. The influence of bacteria with or without the Notch blocker dibenzazepine (DBZ) and of several cytokines on OLFM4 expression was determined in LS174T cells.
resultsOLFM4 mRNA and protein were significantly upregulated in inflamed CD (4.3 and 1.7-fold) and even more pronounced in UC (24.8 and 3.7-fold). OLFM4 expression was correlated to IL-8 but not to Hath1. In controls immunostaining was restricted to the lower crypts but in inflamed IBD it expanded up to the epithelial surface including the mucus. OLFM4 bound to HBD1-3 without profoundly inactivating these defensins. In LS174T-cells OLFM4 mRNA was significantly augmented after incubation with Escherichia coli K12, Escherichia coli Nissle and Bacteroides vulgatus. DBZ downregulated OLFM4 expression and blocked bacterial induction whereas IL-22 but not TNF-α was stimulatory.
conclusionsOLFM4 is overexpressed in active IBD and secreted into mucus. The induction is triggered by bacteria through the Notch pathway and also by the cytokine IL-22. OLFM4 seems to be of functional relevance in IBD as a mucus component, possibly by binding defensins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.